psalexa
logo

IgA Nephropathy Pipeline Analysis

IgA Nephropathy Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: April 2017
Report Code: LS10912
Available Format:
Pages: 81

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

This report includes the IgA nephropathy pipeline analysis as of March 2017, to estimate and analyze the emerging therapies and their progress status in different phases of development. The report also contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to IgA nephropathy.

IgA Nephropathy Pipeline Analysis

  • By phase
    • Phase III
    • Phase II
    • Pre-Clinical
    • Inactive
    • Discontinued

Note: In the pipeline analysis, inactive and discontinued products have been analyzed separately.

  • By route of administration
    • Oral
    • Subcutaneous
    • Not Disclosed
  • By target
    • A Proliferation-Inducing Ligand (APRIL)
    • B Lymphocyte Stimulator (BlyS)
    • Spleen Tyrosine Kinase (SYK)
    • Others
  • By company

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry